Randomized trial · people
Teriparatide: more bony union at 6 months than zoledronate after PLIF
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, teriparatide sped early bone healing and raised bone density more than zoledronate after lumbar fusion, but final fusion rates ended up similar.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 77
- Published
- 2022
- Journal
- World Neurosurg
What they tested
The team tested whether teriparatide or zoledronate works better for spinal fusion in women with osteoporosis after posterior lumbar interbody fusion (PLIF), a type of lower-back fusion surgery.
How the study was done
A randomized trial in postmenopausal women with osteoporosis who had PLIF for degenerative spondylolisthesis, a slipped vertebra from wear and tear. They were assigned to teriparatide or zoledronate, and 77 completed 2 years of follow-up (36 teriparatide, 41 zoledronate).

What they found
Bony union, where the fused bones knit together, was reached more often with teriparatide than with zoledronate at 6 months (P < 0.05), but the overall union rate was similar between groups. Hardware-related problems (a combined count of fractures in the next vertebra, hardware failure and fusion failure) were similar: 13.9% with teriparatide vs 22.0% with zoledronate. Bone mineral density (BMD, a measure of bone strength) rose in both groups, with a bigger gain in the teriparatide group at 12 months. Scores on the Oswestry disability index (ODI, a back-pain disability score where lower is better) fell in both groups and were lower with teriparatide at 12 months.
What it doesn’t show
This was a small trial of 77 women, all postmenopausal with osteoporosis and one kind of spine condition, so it may not apply to men or other surgeries. It compared two active drugs without a placebo group, and the counts cover only the women who finished the 2-year follow-up.
The paper
Xiong et al. Effect of Teriparatide Versus Zoledronate on Posterior Lumbar Interbody Fusion in Postmenopausal Women with Osteoporosis. World Neurosurg. 2022.
The compound
More studies on Teriparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)Meta-analysis · people · 2024
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeksRandomized trial · people · 2020
- Teriparatide: fewer new vertebral fractures than risedronate in VERORandomized trial · people · 2018
- Teriparatide then denosumab: spine density up 18.3% over 4 yearsRandomized trial · people · 2015
- Every study on Teriparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.